Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    87,360.96
    -1,594.22 (-1.79%)
     

  • CMC Crypto 200

    1,383.71
    -12.82 (-0.92%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT RESULTS

Chevron, Exxon under pressure as falling natural gas prices hit earnings

J&J (JNJ) Seeks EU Approval for Darzalex's Expanded Use

Zacks Equity Research
Updated

Johnson & Johnson’s JNJ Janssen-Cilag International NV announced that it has filed a type II variation application with the European Medicines Agency seeking label expansion for its immunotherapy, Darzalex, in combination with Revlimid (an immmunomodulatory agent) and dexamethasone, or Velcade (a proteasome inhibitor/PI) and dexamethasone, for the treatment of adult patients with relapsed multiple myeloma patients who have received at least one prior therapy.

Darzalex gained conditional approval in the EU in May 2016 for use as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunotherapy agent and who have demonstrated disease progression on the last therapy.

The EU filing came a week after the submission of a supplemental biologics license application for a label expansion of Darzalex to the FDA. The company is looking to get Darzalex approved in combination with Revlimid and dexamethasone, or Velcade and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

We note that last month, Darzalex was granted Breakthrough Therapy status by the FDA for this indication. This marks the second time that the drug was granted such status in the U.S. This status expedite the process of development and review of drugs that are being evaluated for the treatment of serious or life-threatening diseases, where preliminary clinical evidence indicates that the drug may provide substantial improvement over existing therapies.

ADVERTISEMENT

JOHNSON & JOHNS Price

 

 

JOHNSON & JOHNS Price | JOHNSON & JOHNS Quote

We remind investors that Janssen Biotech, Inc. had entered into a worldwide agreement with Genmab A/S GNMSF in Aug 2012, whereby the former was granted an exclusive license to develop, manufacture and commercialize Darzalex. The submission of the application triggered milestone payments of $10 million to Genmab from Janssen.

We note that Amgen Inc.’s AMGN Kyprolis is also approved for the treatment of multiple myeloma.

Johnson & Johnson has a Zacks Rank #3 (Hold). Corcept Therapeutics Inc. CORT is a better-ranked stock in the health care sector, sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
 
AMGEN INC (AMGN): Free Stock Analysis Report
 
GENMAB A/S (GNMSF): Free Stock Analysis Report
 
CORCEPT THERAPT (CORT): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research